In a groundbreaking study published in the Journal of Clinical Investigation, researchers have delineated the distinct roles of hypoxia-inducible factor isoforms HIF1α and HIF2α in skeletal muscle metabolism and systemic physiology. Skeletal muscle, a metabolically demanding tissue crucial for movement and posture, is vulnerable to oxygen deprivation during intense or prolonged exercise. This new research reveals that HIF1α and HIF2α exert separate regulatory effects, challenging the traditional perspective of muscle oxygen sensing as a unified mechanism.
Utilizing sophisticated myofiber-specific mouse models, the team led by Professors Dong-il Kim and Min-Jung Park strategically manipulated the activity of HIF pathways. They engineered models with either all three prolyl hydroxylase domains (PHDs) knocked out—enzymes that normally inhibit HIF activation—or selectively stabilized HIF1α or HIF2α within skeletal muscle fibers. This precise approach allowed for direct comparison of the individual contributions of these isoforms to muscle and systemic metabolism.
The findings were surprising. Stabilization of HIF1α increased the proportion of oxidative muscle fibers—cells typically associated with endurance capacity. Despite this morphological shift, the mice exhibited impaired performance in treadmill endurance tests and compromised mitochondrial oxidative phosphorylation, indicating that the underlying energy production machinery was dysfunctional even though the muscle phenotype suggested endurance adaptation.
In contrast, activation of HIF2α produced markedly different physiological outcomes. Mice with stabilized HIF2α displayed improved glucose tolerance, reduced weight gain, and preservation of mitochondrial function. Intriguingly, these mice also showed decreased food intake alongside elevated circulating levels of glucagon-like peptide-1 (GLP-1), hinting at a systemic metabolic influence mediated by muscle HIF2α pathways.
One of the most unexpected discoveries was HIF2α’s role in promoting erythropoietin (EPO) synthesis directly within skeletal muscle fibers. Traditionally, EPO—an essential hormone for red blood cell production—is synthesized by the kidneys and liver. However, selective deletion of muscle-derived EPO in the PHD triple-knockout mice normalized previous hematological abnormalities, confirming that the PHD-HIF2α axis can drive myofiber-specific EPO production. This positions skeletal muscle as an auxiliary endocrine organ capable of influencing erythropoiesis under hypoxic stress.
These insights carry significant implications for understanding the complex interplay between muscle physiology, metabolism, and systemic oxygen transport. They also raise critical considerations regarding pharmacological interventions targeting PHD and HIF pathways, which are currently explored for anemia therapies. The distinct and sometimes opposing effects of HIF1α and HIF2α underscore the necessity for isoform-specific strategies to avoid unintended consequences such as muscle dysfunction or erythrocytosis.
While these findings open exciting avenues for metabolic disease treatment and the development of exercise intolerance therapies, researchers caution that results derived from mouse models require further validation in human studies. Moreover, the inducible nature of muscle-derived EPO suggests a potential compensatory mechanism during compromised renal EPO production, offering new perspectives on managing anemia.
Overall, this study exemplifies the dynamic role of skeletal muscle not only as a locomotive tissue but also as a critical player in endocrine and metabolic regulation, driven by finely tuned hypoxia-sensing pathways.
Subject of Research: Animals
Article Title: Distinct HIF1α and HIF2α functions control skeletal muscle metabolism and erythropoiesis
News Publication Date: 15-Apr-2026
Web References: https://www.jci.org/articles/view/195411
References: DOI: 10.1172/JCI195411
Image Credits: Prof. Min-Jung Park
Keywords: Skeletal muscle, HIF1α, HIF2α, metabolism, erythropoiesis, hypoxia, erythropoietin, mitochondrial function, glucose tolerance, PHD inhibitors
